ACADIA Pharma launches mid-stage study of pimavanserin in Alzheimer’s agitation

Short resume:

pharmaceuticals
90%
agitation
80%
acadia
70%
acad
60%
ACADIA Pharma launches mid-stage study of pimavanserin in Alzheimer's agitation

ACADIA Pharmaceuticals (ACAD -0.2%) initiates a Phase 2 clinical trial, SERENE, assessing pimavanserin (NUPLAZID) for the treatment of agitation in Alzheimer’s disease (AD) patients, a common condition in AD sufferers and a major cause of distress for …
Source Seeking Alpha
Read More…

More News

Be the first to comment

Leave a Reply

Your email address will not be published.


*